AMLX · NASDAQ · Pharmaceutical Preparations
Pharmaceutical Preparations company based in Cambridge, Ma.
In the last 90 days, no insider of Amylyx Pharmaceuticals reported an open-market purchase and 0 open-market sales. Every figure links to its official SEC, House, Senate or USAspending record.
Last closeLast close, Oct 6, 2026
$28.04
Last 12 months
Not enough history
Market value
Not available
Bets against the stock: 13.5M shares sold short, +6.1% vs the previous count, 8.6 days of normal trading to buy them back. FINRA, as of Sep 15, 2026.
Revenue
—
Year earlier: $0
Free cash flow, last 12 months
—
Cash from operations minus capital spending
Net debt
—
Debt —, cash $49.3M, at Jun 30, 2026
Net income, last 12 months
−$152M
From the company's own quarterly and annual reports to the SEC. Free cash flow (cash from operations minus capital spending), net debt (debt minus cash) and 12-month totals are calculated by OQRO. Production rates, deliveries, approvals and guidance are in its results announcement of Aug 6, 2026.
Insiders buying, last 90 days
None
No open-market purchases reported
Insiders selling, last 90 days
None
No open-market sales reported
New federal contracts, 12 months
None
Nothing found for this company
Traded Oct 5 · filed the same day
A Amylyx Pharmaceuticals director told the SEC about a plan to sell $2.78M of Amylyx Pharmaceuticals shares around Oct 5, 2026. The shares were not acquired as compensation. That is a tiny part of all Amylyx Pharmaceuticals shares.
Prices are daily closes from Polygon.io. Company figures come from its own SEC filings. Past moves are not a forecast. OQRO reports what was filed and never tells you what to buy or sell.
1 active phase 3 trial and 1 active phase 2 trial led by this company, mostly in wolfram syndrome, post bariatric hypoglycemia.
2 trials have a registered primary completion date that has already passed. That usually means the data are being analysed, or the entry has not been updated.
Source: ClinicalTrials.gov, studies whose lead sponsor is the company or a listed subsidiary. “Primary completion” is the sponsor's own registry date for the last main data collection. It is not an approval date, it says nothing about the result, and it is often revised.
Fails to deliver: 64K shares (about $2.24M) were not delivered on time for settlement on Aug 19, 2026. SEC fails-to-deliver data.
Fails to deliver have many causes, including processing delays, and are often resolved within days.
